Skip to main content

Clinical Response Seen for Patients With Severe Asthma Initiating Biologics

Medically reviewed by Carmen Pope, BPharm. Last updated on June 28, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, June 28, 2024 -- Patients with severe asthma initiating biologics exhibit clinical responses and super-responses, but 40 to 50 percent do not meet response criteria, according to a study published online June 22 in Allergy.

Eve Denton, M.B.B.S., from Alfred Health in Melbourne, Australia, and colleagues examined responsiveness to biologics in a real-world population of adults with severe asthma. Participants in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow-up were categorized as those who initiated or did not initiate biologics. Treatment responses were examined in various domains: forced expiratory volume in one second (FEV1) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50 percent, and any long-term oral corticosteroids (LTOCS) dose reduction. Overall, 5.3 percent of the patients in ISAR met the inclusion criteria for the trial; 2,116 of 8,451 initiated biologics.

The researchers found that compared with noninitiators, biologic initiators had worse baseline impairment, despite having similar biomarker levels. Of the initiators, about half or more had treatment responses: 59 percent AER reduction, 54 percent FEV1 increase, 49 percent improved control, and 49 percent reduced LTOCS; of these, 32, 19, 30, and 39 percent, respectively, were super-responses. Compared with noninitiators, biologic initiators more often had responses/super-responses; however, about 40 to 50 percent of initiators did not meet the criteria for response.

"These findings justify further research to determine whether initiating biologics earlier -- before asthma causes irreversible lung damage -- may increase the likelihood of achieving a response or super-response," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including AstraZeneca and Optimum Patient Care Ltd., which funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Antibiotic Exposure Before Age 2 May Increase Risk for Chronic Pediatric Conditions

WEDNESDAY, April 30, 2025 -- Children receiving multiple antibiotic courses between birth and age 2 years may have a higher risk for some chronic conditions, according to a study...

School-Based Asthma Therapy Boosts Asthma Control, Cuts Acute Health Care Use

THURSDAY, April 24, 2025 -- School-based asthma therapy (SBAT) can help improve children’s asthma control and decrease acute health care utilization, according to a study...

Midafternoon Dosing Improves Lung Function in Atopic Asthma

FRIDAY, April 18, 2025 -- Midafternoon dosing with beclomethasone dipropionate is associated with better clinical outcomes in mild-to-moderate atopic asthma, according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.